Greg Hoffman work email
- Valid
- Valid
- Valid
- Valid
Greg Hoffman personal email
Experienced leader in discovery and platform development for cell and gene therapy. Trained biophysicist & cell biologist with a career focus on applying innovative technologies to study the molecular basis of disease and develop medicines. 10+ years industry experience leading teams focused on genomic screening for early target discovery, small molecule discovery, synthetic biology, and cell and gene therapy. Effective leadership in establishing new technologies, building collaborative interdisciplinary teams, and building biotech and academic partnerships.
-
Chief Scientific OfficerDeep Genomics Jun 2024 - PresentToronto, CaDeep Genomics is an interdisciplinary team of machine learning and drug development scientists working to decode RNA biology, discover novel targets, and design and develop oligo-based therapeutics. Working with partners, we apply our AI Foundation Models to accelerate discovery and improve the success of translating these discoveries to the clinic. -
Vice President Platform BiologyDeep Genomics Feb 2024 - Jun 2024Toronto, Ca
-
Vice President Discovery & PlatformArbor Biotechnologies May 2021 - Feb 2024Cambridge, Massachusetts, UsAt Arbor Biotechnologies, we are uncovering novel gene editors and developing them into powerful tools in our quest for curative treatments for previously incurable genetic disease. The Discovery & Platform team uses high-throughput screening capabilities to characterize novel gene editing enzymes identified by Arbor’s powerful computational search capabilities. We apply protein engineering and directed evolution techniques to optimize gene editing activity to tailor their activity for specific therapeutic applications. This work is enabled by a world class suite of platform technologies in genomics, microfluidics, automation, & protein biochemistry. -
Senior Director, DiscoveryObsidian Therapeutics Jun 2020 - May 2021Cambridge, Ma, UsI lead the Discovery Group at Obsidian Therapeutics, where we are pioneering the development of controllable cell and gene therapies using our cytoDRiVE technology to deliver transformative outcomes for patients with intractable diseases. The Discovery team applies state-of-the-art functional screening technologies to identify new target opportunities and optimize the design of lead candidates to accelerate Obsidian’s therapeutic pipeline. We apply synthetic biology to develop new control circuits and validate new therapeutic applications of the cytoDRiVE platform. -
Senior Director, Head Of Cell TechnologiesSana Biotechnology, Inc. Nov 2018 - May 2020Seattle, Washington, UsResponsible for building technology platforms to drive all stages of our Sana's cell & gene therapies pipeline, from early discovery through scale-up and manufacturing across multiple sites including Cambridge, San Francisco, & Seattle. -
Investigator Ii - Sr. Investigator INovartis Institutes For Biomedical Research May 2011 - Nov 2018Basel, Baselstadt, ChI lead the Technologies Targets and Leads (T2L) group in Screening Sciences at NIBR focused on developing and deploying novel screening technologies for target & lead discovery. Our goal is to identify proprietary therapeutic targets for the NIBR pipeline in areas of high unmet medical and drive these projects through the early phase of lead discovery in collaboration with disease area experts covering a broad range of indications including Oncology/Immuno-Oncology, Neuroscience, Ophthalmology, and Infectious Disease. -
Postdoctoral FellowHarvard Medical School 2002 - 2011Boston, Ma, UsLAM Foundation Postdoctoral Fellow (Nov. 2004-May 2011) Principal Investigator: Dr. John BlenisElucidating the mechanisms of growth factor and nutrient regulation of mTORC1Helen Hay Whitney Postdoctoral Fellow (Oct. 2002 – Oct. 2004) Principal Investigator: Dr. Marc KirschnerBiochemical studies of MAP-kinase signal specificity in Xenopus egg extracts
Greg Hoffman Skills
Greg Hoffman Education Details
-
Cornell UniversityBiophysics -
Cornell UniversityBiochemistry
Frequently Asked Questions about Greg Hoffman
What company does Greg Hoffman work for?
Greg Hoffman works for Deep Genomics
What is Greg Hoffman's role at the current company?
Greg Hoffman's current role is Chief Scientific Officer at Deep Genomics.
What is Greg Hoffman's email address?
Greg Hoffman's email address is gh****@****ntx.com
What schools did Greg Hoffman attend?
Greg Hoffman attended Cornell University, Cornell University.
What skills is Greg Hoffman known for?
Greg Hoffman has skills like Cell Biology, Drug Discovery, Molecular Biology, Biochemistry, Cell Culture, High Throughput Screening, Cell, Assay Development, In Vitro, Life Sciences, Protein Chemistry, Lifesciences.
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial